TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02945696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic guided nerve blocks
Description: It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
Study: NCT00626015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given by mouth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3-KLH
Description: Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
Study: NCT03079076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml %0,25 bupivacaine bilaterally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml saline subcutaneously bilaterally
Study: NCT04931719

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP+Artz group
Description: The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+Artz group
Description: The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP+ HYAJOINT Plus group
Description: The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+ HYAJOINT Plus group
Description: The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
Study: NCT01380691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching alcoholic beverage
Description: Administered orally
Study: NCT03194945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII followed by Lina+MET
Description: short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII followed by Lina
Description: short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII followed by MET
Description: short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII alone
Description: No OHA is given after short-term intensive CSII
Study: NCT02360865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT02801864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Speech Therapy
Description: Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intensive Speech Therapy
Description: Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
Study: NCT02109666

Intervention type: DRUG
Intervention: Abatacept
Study: NCT00530998

Intervention type: PROCEDURE
Intervention: Transvaginal Appendectomy
Description: The appendix will be removed via an incision in the vagina.

Intervention type: PROCEDURE
Intervention: Transvaginal Cholecystectomy
Description: The gallbladder will be removed via an incision in the vagina.
Study: NCT02505477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
Study: NCT04063046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block
Description: ultrasound-guided popliteal sciatic nerve block is performed
Study: NCT02964546

Intervention type: OTHER
Intervention: Blood sample
Description: 2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
Study: NCT02238106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol medium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent® Diskus®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo HandiHaler®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo HandiHaler®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diskus®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Diskus®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Diskus®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Diskus®
Study: NCT03253068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus amurubicin
Description: Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
Study: NCT04198493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment every night plus conservative treatment for OSA: sleep hygiene and dietary counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONSERVATIVE TREATMENT for OSA
Description: Conservative treatment for OSA: sleep hygiene and dietary counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONSERVATIVE TREATMENT for OSA
Description: Conservative treatment for OSA: sleep hygiene and dietary counseling
Study: NCT03428464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
Study: NCT04176133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Study: NCT03428464

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
Study: NCT03470792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcirculation examination
Description: Sublingual microcirculation images were recorded using an incident dark-field video microscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcirculation examination
Description: Sublingual microcirculation images were recorded using an incident dark-field video microscope
Study: NCT01544504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
Study: NCT04176133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Influenza vaccine
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Study: NCT04404621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) training and computer-based brain (CBB)
Description: 18 weeks of PE and CBB.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) training and computer-based brain (CBB)
Description: 18 weeks of PE and CBB.
Study: NCT00003534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02250521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC enhanced direct laryngoscope
Description: The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
Study: NCT03656484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline-Metronidazole (TM) group
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM-Melatonin-Hyaluronic acid (TM-MHa) group
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Study: NCT00289770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™
Description: Intramuscular injection, 3 doses
Study: NCT01905579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracentesis of the anterior chamber
Description: Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracentesis of the anterior chamber
Description: Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
Study: NCT04328558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clavipectoral fascia plane block group
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT03200301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intact Umbilical Cord Milking
Description: Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
Study: NCT01973894

Intervention type: PROCEDURE
Intervention: Blood and urine sampling
Description: Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations.
Study: NCT04446910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: SMS text messaging intervention for a period of 90 days to promote attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Engagement Practices
Description: Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
Study: NCT00861796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYR-101
Description: Experimental arm
Study: NCT01380691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching alcoholic beverage
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching alcoholic beverage
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching alcoholic beverage
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Administered orally
Study: NCT02651688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enclomiphene
Description: Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enclomiphene
Description: Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Study: NCT02084914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Description: Group A: pipelle Group B: sound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: Group A: pipelle Group B: sound
Study: NCT03582319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
Study: NCT01590849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptives, Oral, Combined (Yaz®)
Description: After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use.
Study: NCT00815334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic subureteric injection
Description: Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic subureteric injection
Description: Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
Study: NCT03284112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Old SCHOOL Hip-Hop
Description: A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: My Plate
Description: The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program.
Study: NCT03230136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal cardioprotection strategy
Description: Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard anesthetic procedure
Description: standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
Study: NCT03717168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone
Description: All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: All patients will not receive growth hormone.
Study: NCT01200485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2.